Comments
Johnson & Johnson on Tuesday announced sales of $17.6 billion in the third quarter of 2013, an increase of 3.1 per cent over the third quarter last year.
The world’s biggest maker of health-care products reported net earnings of $3 billion for the quarter as new drugs helped Johnson & Johnson’s pharmaceutical business deliver strong results, the company said.
Johnson & Johnson has begun selling eight new medicines since 2011, including the blood thinner Xarelto and prostate cancer treatment Zytiga. Worldwide Pharmaceutical sales amounted to $7 billion in the third quarter, an increase of 9.9 per cent over the same quarter in 2012.
Worldwide consumer sales increased to $3.6 billion in the third quarter, a rise of 0.8 per cent over the prior year.
The third-quarter results included after-tax special items adding up to about $900 million, primarily related to an increase in accrual for litigation expenses, in-process research and development expenses and costs related to the acquisition of Synthes.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.